Current Edition

Regional News

GlaxoSmithKline’s HIV drug Cabenuva scores FDA nod for 2-month dosing

Last January, when GlaxoSmithKline’s ViiV Healthcare won a long-awaited approval for its long-acting HIV treatment Cabenuva, it was hailed as a game-changer as it rem...
Continue Reading →
Regional News

Johnson & Johnson CEO: Consumer health split won’t interfere with our ‘more aggressive’ approach to M&A

For anyone playing a drinking game, taking a sip each time the phrase “the new Johnson & Johnson,” was uttered during the company’s fourth-quarter earnings call o...
Continue Reading →
Regional News

Verana Health lands J&J, Novo backing in $150M round to fund real-world database for drug, device development

With a new CEO at the helm, the recent launch of an artificial-intelligence-powered data analytics engine and, now, the close of its largest funding round to date, Ve...
Continue Reading →
Regional News

Amid consumer spinoff and CEO transition, Johnson & Johnson names new leadership team

Less than a month after revealing a plan to spin its consumer health business off as a new publicly traded company, Johnson & Johnson has shed more light on its f...
Continue Reading →
Regional News

Aspen closes in on Africa license for Johnson & Johnson’s COVID-19 vaccine

One of Johnson & Johnson’s long-held pandemic manufacturing partners just made headway in its quest to license the company’s shot in Africa. Aspen Pharmacare on ...
Continue Reading →
Regional News

Novartis may have a buyer for $21B generics unit Sandoz

Amid the industrywide push by Big Pharmas to spin off their generics and consumer businesses, Novartis may be on the verge of separating itself from Sandoz. Swedish-...
Continue Reading →
Regional News

J&J’s Invokana chases AZ’s Farxiga and Lilly’s Jardiance with phase 3 heart failure win

Chasing rivals from AstraZeneca and Eli Lilly/Boehringer Ingelheim, Johnson & Johnson's Invokana is vying for a piece of the lucrative heart failure market. J&am...
Continue Reading →
Regional News

Amid a push to resolve opioid and talc claims, Johnson & Johnson settles Risperdal litigation for $800M

Over the last few months, Johnson & Johnson has made sweeping moves to resolve a mountain of litigation involving the safety and marketing of its opioid and talc ...
Continue Reading →
Regional News

Johnson & Johnson wins FDA panel backing for a second dose of its COVID shot but don’t call it a ‘booster’

Over the last year, the Johnson & Johnson COVID-19 vaccine has been commonly referred to as a single-shot alternative to the two-dose regimens of mRNA vaccines fr...
Continue Reading →
Regional News

GlaxoSmithKline’s long-acting HIV drug nabs FDA priority review as a preventative option

GlaxoSmithKline’s long-acting HIV drug cabotegravir is already challenging market leaders as part of an approved treatment regimen. Now, the medicine is a step closer...
Continue Reading →